CASE REPORT

Graves’ disease coexisted with resistance to thyroid hormone: a case report

Hiroshi Akahori1* and Rika Usuda2

Abstract

Background: Resistance to thyroid hormone is a rare autosomal dominant disorder characterized by reduced responsiveness to thyroid hormone and can cause syndrome of inappropriate secretion of thyroid stimulating hormone. Although Graves’ disease is a common autoimmune thyroid disorder, the coexistence of these two diseases is extremely rare and makes the diagnosis and treatment complicated, leading to the delayed diagnosis of resistance to thyroid hormone. We describe the case of a Japanese man with resistance to thyroid hormone coexisting with Graves’ disease, in which the correct diagnosis of resistance to thyroid hormone was delayed by masking of the signs of syndrome of inappropriate secretion of thyroid stimulating hormone, with final diagnosis 30 years after the initial treatment for Graves’ disease.

Case presentation: A 30-year-old Japanese man presented with diffuse goiter and thyrotoxicosis. Anti-thyroid stimulating hormone receptor antibody was positive. He was diagnosed with Graves’ disease. Anti-thyroid medication was chosen as the initial treatment for Graves’ disease. However, this treatment failed to normalize the free triiodothyronine, free thyroxine, and thyroid stimulating hormone levels. His thyroid hormone levels indicated syndrome of inappropriate secretion of thyroid stimulating hormone. After cessation of methimazole treatment by remission of Graves’ disease, his state of syndrome of inappropriate secretion of thyroid stimulating hormone persisted. Magnetic resonance imaging revealed no pituitary tumor lesions. The results of thyroid stimulating hormone-releasing hormone stimulation test showed a normal response of thyroid stimulating hormone. He was suspected to have resistance to thyroid hormone. Direct sequencing analysis of the thyroid hormone receptor β gene identified a heterozygous missense mutation, R282S. Coexistence of resistance to thyroid hormone with Graves’ disease was confirmed. He has no signs of thyrotoxic symptoms, and is capable in activities of daily living at the present time.

Conclusion: We described a rare case of resistance to thyroid hormone simultaneously existing with Graves’ disease. This case demonstrated that these diseases can coexist, and indicated some of the difficulties in diagnosis of resistance to thyroid hormone with coexisting Graves’ disease. The diagnosis of resistance to thyroid hormone did not become apparent until after anti-hyperthyroidism treatment. Although rare, careful follow-up after the initial treatment of Graves’ disease is necessary. The coexistence of these two diseases should be considered in patients showing occasional syndrome of inappropriate secretion of thyroid stimulating hormone.

Keywords: Graves’ disease, Resistance to thyroid hormone, Thyroid hormone receptor β, R282S, Syndrome of inappropriate secretion of TSH

Background

Resistance to thyroid hormone (RTH) is an autosomal dominant disorder characterized by reduced responsiveness of variable tissues to thyroid hormone [1, 2]. The human thyroid hormone receptor (TR) is expressed by...
two genes, TRβ and TRα, which have several isoforms generated by alternative splicing. TRβ1 is expressed in the liver, kidney, and brain, while TRβ2 is expressed in the anterior pituitary and hypothalamus, and is mainly involved in the negative feedback regulation of thyroid stimulating hormone (TSH) by thyroid hormone in the anterior pituitary. RTH is mainly caused by germline mutations of TRβ, localized to the ligand-binding domain [3–5]. The mutant receptors show reduced ligand binding, and inhibit wild-type TR action in a dominant negative manner [6]. This syndrome was first reported by Refetoff et al. in 1967 [7]. The syndrome of inappropriate secretion of TSH (SITSH) showing elevated serum levels of free thyroxine (FT4) and free triiodothyronine (FT3) with normal or slightly elevated TSH levels (non-suppressed TSH) is a hallmark of RTH as well as TSH producing pituitary tumors [8].

Graves’ disease is a common autoimmune thyroid disorder, which is responsible for approximately 50–80% of cases of thyrotoxicosis in Japan. In Graves’ disease, the circulating immunoglobulin G antibodies bind to the G-protein-coupled TSH receptor, and increase thyroid hormone production, causing hyperthyroidism. This disorder shows elevated FT3 and FT4 with suppression of TSH to below the level of detection, as opposed to RTH.

Thus, the coexistence of these two diseases makes the diagnosis and treatment complicated. Here, we describe a rare case of RTH coexisting with Graves’ disease, in which the correct diagnosis of RTH was delayed by masking of the signs of SITSH, with final diagnosis due to the inappropriately elevated TSH level after treatment of anti-hyperthyroidism.

Case presentation

A 30-year-old Japanese man was referred to our hospital because of fatigue, palpitation, body weight loss, finger tremor, and heat intolerance for 3 months. He was 166.2 cm in height and 60.2 kg in weight. His blood pressure was 110/50 mmHg, and his heart rate was 70 beats/minute and regular. His body temperature was 36.3 °C. The thyroid gland was slightly enlarged, non-tender, and softly elastic on palpation. Exophthalmos was not observed. Thyroid function test demonstrated elevated levels of FT3 and FT4, and complete suppression of TSH level, which was below the limit of detection. Serum anti-TSH receptor antibody (TRAb), anti-thyroid peroxidase antibody (TPOAb), and anti-thyroglobulin antibody (TgAb) were positive. Ultrasonography of the thyroid gland revealed diffuse enlargement without tumor lesions. The right and left lobes of the thyroid gland measured 49 × 24 × 20 mm and 54 × 22 × 20 mm, respectively. These results indicated that Graves’ disease was responsible for primary hyperthyroidism in this case. A diagnosis of Graves’ disease was made based on these findings. Methimazole (MMI) therapy was started at 15 mg/day. His symptoms improved gradually, and the dosage of methimazole was decreased as thyroid function normalized. After 6 months, methimazole therapy was continued at 10 mg/day, and the levels of TSH, FT3, and FT4 were maintained within the respective normal ranges. He was transferred to a local hospital. His thyroid function was followed up periodically, and the levels of FT3 and FT4 were elevated, but TSH levels were within normal range or slightly elevated on some occasions. At the age of 48 years, he was referred to our hospital for further endocrinological examination. On physical examination, his height was 165.4 cm, body weight was 58.6 kg, body mass index was 22.1 kg/m², blood pressure was 122/70 mmHg, and his pulse was regular at 80 beats/minute. His body temperature was 36.8 °C. The thyroid was diffusely enlarged, softly elastic, and non-tender on palpation. Exophthalmos was not observed. Laboratory findings are presented in Table 1. The results of thyroid function tests with methimazole treatment at 10 mg/day revealed serum levels of FT3, FT4, and TSH of 5.4 pg/mL (normal range 2.4–4.3 pg/mL), 1.7 ng/dL (normal range 0.9–1.8 ng/dL), and 4.77 μIU/mL (normal range 0.35–4.94 μIU/mL), respectively, indicating SITSH. Chest X-ray and electrocardiographic findings were normal. His bone mineral density was 0.712 g/cm² (88% of the young adult mean) in the femur. He showed no stigmata of thyrotoxicosis. Ultrasonography of the thyroid showed diffuse enlargement of both lobes with no tumor lesions. Increased blood flow was not detected on Color-Doppler imaging (Fig. 1). Thyroid radioactive 123I uptake was 11.8% in 3 hours (reference range, 5–15%) (Fig. 2). The titer of TRAb was weakly positive, and the dosage of methimazole was decreased gradually to maintain normal TSH level (Fig. 3). Six years after he visited our hospital, methimazole treatment was ceased, and the titer of TRAb became negative. These findings indicated that Graves’ disease was in remission. The symptoms of hyperthyroidism, such as finger tremors, palpitations, and weight loss, were not observed. After cessation of methimazole treatment, his thyroid hormone levels fluctuated and showed occasional elevation of FT3 or FT4 with normal TSH level. His state of SITSH persisted. Magnetic resonance imaging (MRI) was performed for the differential diagnosis of TSH producing pituitary tumor, and revealed no tumor lesions. The results of TSH-releasing hormone (TRH) stimulation test are presented in Table 2. His TSH level showed a normal response to TRH stimulation. He was suspected to have RTH. A genetic investigation was conducted with the
patient’s written informed consent. Blood samples were obtained, and genomic DNA was isolated from leukocytes. Direct sequencing analysis of the TRβ gene identified a heterozygous, missense point mutation in exon 8, AGA to AGC, resulting in substitution of arginine by serine at codon 282 (R282S) (Fig. 4). He reported no thyroid disease in his family. Thyroid function tests and DNA analysis were not performed for other family members, because they declined to provide consent.

At the time of writing, he has no signs of thyrotoxic symptoms. His pulse rate is regular at 80–90 beats/minute. He is comfortable at rest, and capable in activities of daily living.

**Discussion and conclusions**

RTH is a rare autosomal dominant disorder characterized by reduced responsiveness to thyroid hormone, and is estimated to affect approximately 1 per 40,000

### Table 1 Laboratory data on arrival

| Urinalysis       | Biochemistry | Endocrinological examination |
|------------------|--------------|------------------------------|
| Color Yellow     | LDH 181 IU/L | TSH 4.77 μIU/mL (0.35–4.94) |
| pH 6.5           | ALP 191 IU/L | FT3 5.4 pg/mL (2.4–4.3)     |
| Glucose (−)      | γ-GTP 33 IU/L| FT4 1.7 ng/dL (0.9–1.8)     |
| Protein (−)      | CK 151 IU/L | Tg 3.0 ng/mL (0–33.7)       |
| Occult blood (−) | LDL-C 121 mg/dL | TRAb 3.9 IU/L (0–1.0) |
| Ketone (−)       | TG 146 mg/dL | TSAb 269% (0–120)          |
| Hematology       |              |                             |
| WBC 5600/μL      | K 4.2 mEq/L  | ACTH 18.4 pg/mL (7.2–63.3) |
| RBC 485 × 10^6/μL| CI 102 mEq/L| cortisol 9.9 μg/dL (4.5–21.1)|
| Hb 13.5 g/dL     | Ca 9.4 mEq/L | GH 0.48 ng/mL (0.13–0.88)  |
| Ht 45.6%         | P 4.9 mEq/L | IGF-1 127 ng/mL (89–248)   |
| Plts 26.4 × 10^5/μL | BUN 16 mg/dL | PRL 7.72 ng/mL (3.6–12.8) |
| CRP 0.1 mg/dL    | Cr 0.7 mg/dL | FSH 6.74 μIU/mL (2.0–8.3)  |
| TP 7.5 g/dL      | UA 6.7 mg/dL | LH 5.29 μIU/mL (0.8–5.7)   |
| Alb 4.5 g/dL     | FPG 81 mg/dL |                             |
| T-Bil 0.47 mg/dL | HbA1c 5.50% |                             |
| AST 22 IU/L      |              |                             |
| ALT 19 IU/L      |              |                             |

γ-GTP: γ-glutamyl transpeptidase; ACTH: adrenocorticotropic hormone; Alb: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CK: creatine kinase; Cr: creatine; CRP: C-reactive protein; FPG: fasting plasma glucose; FSH: follicle stimulating hormone; FT3: free triiodothyronine; FT4: free thyroxine; GH: growth hormone; Hb: hemoglobin; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein-cholesterol; HD: hematocrit; IGF-1: insulin-like growth factor-1; LDH: lactate dehydrogenase; LDL-C: low-density lipoprotein-cholesterol; LH: luteinizing hormone; Plts: platelets; PRL: prolactin; RBC: red blood cells; T-Bil: total bilirubin; TG: triglyceride; Tg: thyroglobulin; Tg Ab: anti-thyroglobulin antibody; TP: total protein; TPO Ab: anti-thyroid peroxidase antibody; TRAb: anti-TSH receptor antibody; TSAb: thyroid-stimulating antibody; TSH: thyroid-stimulating hormone; UA: uric acid; WBC: white blood cells

**Fig. 1** Thyroid ultrasonography showed diffuse enlargement of both lobes with heterogeneous echogenicity. No tumor lesions were detected. Neither lobe showed increased blood flow on Color-Doppler imaging.
newborn infants [9]. Thyroid hormones have roles in a range of functions, including energy homeostasis, cardiac and gastrointestinal function, and maturation of the central nervous system. These actions are mediated by TRs encoded by two genes: TRβ and TRα. This syndrome is associated with germline mutations of TRβ. TRβ gene encodes two isoforms by alternative splicing, TRβ1 and TRβ2. TRβ1 is widely expressed, especially in the liver and kidney. TRβ2 is expressed in the anterior pituitary and hypothalamus, and mainly contributes to the negative feedback regulation of TSH by thyroid hormone in the anterior pituitary. RTH is associated with genetic mutations in the ligand-binding domain of TRβ, which is common between TRβ1 and TRβ2. Thus, mutations of TRβ cause failure of this negative feedback regulation of TSH by thyroid hormone, and can cause SITSH. The pathogenesis of RTH is related to the distributions of TRβ and TRα in different tissues, and dominant negative activity of mutant receptors on different target genes. Resistance to thyroid hormone is compensated by increased thyroid hormone levels. Therefore, the patients with RTH have no severe symptoms of hypothyroidism.

Here, we reported a Japanese man with RTH concomitant with Graves’ disease. In the onset of Graves’ disease, his TSH values were suppressed below the limit of detection. Furthermore, he showed the apparent features of hyperthyroidism, such as general fatigue, palpitation, body weight loss, finger tremor, and heat intolerance. These observations indicated that peripheral tissues were responsive to excess thyroid hormone. Therefore, the

Table 2 Thyrotropin-releasing hormone stimulation test

| Time (minutes) | Basal | 30   | 60   | 90   | 120  |
|---------------|-------|------|------|------|------|
| TSH (μIU/mL)  | 7.24  | 37.5 | 33.3 | 24.0 | 17.4 |
| FT3 (μIU/ml)  | 4.19  | 4.1  | 4.1  | 4.1  | 4.4  |
| FT4 (pg/ml)   | 1.3   | 1.5  | 1.0  | 1.5  | 1.3  |
| ALP (IU/l)    | 3.9   | 2.9  | 2.3  | <1.0 | <1.0 |
| PRL (ng/mL)   | 7.16  | 88.03| 51.12| 29.90| 20.89|

FT3: free triiodothyronine; PRL: prolactin; TSH: thyroid-stimulating hormone

| age (years) | 48 | 50 | 52 | 54 | 58 | 60 |
|------------|----|----|----|----|----|----|
| MMI (mg/day) |    |    |    |    |    |    |
|             | 10 | 5  | 2.5|    |    |    |

Fig. 3 Clinical course after anti-hyperthyroidism treatment for Graves’ disease. Thyroid hormone levels showed occasional SITSH in the periods of anti-hyperthyroidism treatment. Although this treatment led to remission of Graves’ disease, it failed to normalize the FT3, FT4, and TSH levels. SITSH persisted even after cessation of methimazole treatment.
Graves’ disease, and normal or slightly elevated TSH level, although with RTH usually have elevated levels of FT3 and FT4 negative feedback regulatory system by RTH. Patients with RTH may have a hypothyroid state. Therefore, the dosage of anti-thyroid medication should be controlled to maintain slightly elevated levels of FT3 and FT4. The relationship between RTH and Graves’ disease is unclear. Cases of RTH coexisting with chronic thyroiditis, not Graves’ disease, have been reported [14–16]. It has also been reported that patients with RTH have high prevalence of TPOAb and TgAb, indicating the potential interactions between RTH and autoimmune thyroid disease [17]. Moreover, the hypersecretion of TSH may play an important role in the onset of Graves’ disease. TSH has various important actions in the maintenance of normal physiology and in the regulation of immunomodulatory gene expression of thyrocytes. Patients with RTH show elevated production of TSH. It has been reported that the abnormal hypersecretion of TSH in thyrotropin-producing pituitary adenoma can produce anti-idiotypic antibodies, causing Graves’ disease [18–20]. In our case, the elevated TSH levels due to failure of this negative feedback regulation of ‘TSH by thyroid hormone may have produced TRAb and induced the onset of Graves’ disease. The further accumulation of clinical data will be necessary to determine whether germline mutations of TRβ induce autoimmune thyroid disease in patients with RTH.

In conclusion, we described a rare case of RTH simultaneously existing with Graves’ disease. The patient carried a mutation, R282S, in the TRβ gene. This case indicated some of the difficulties in diagnosis of RTH with coexisting Graves’ disease. The diagnosis of RTH did not become apparent until after anti-hyperthyroidism treatment. Careful follow-up is necessary to determine whether secretion of TSH may be inappropriate to regulate thyroid hormone in the periods of anti-hyperthyroidism treatment. The coexistence of these two diseases should be considered in patients showing occasional SITSH.

**Abbreviations**

γ-GTP: γ-Glutamyl transpeptidase; ACTH: Adrenocorticotropic hormone; Alb: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CK: Creatine kinase; CPR: C-peptide immunoreactivity; Cr: Creatine; CRP: C-reactive protein; FPG: Fasting plasma glucose; FSH: Follicle stimulating hormone; FT3: Free triiodothyronine; FT4: Free thyroxine; GH: Growth hormone; Hb: Hemoglobin; HbA1c: Glycated hemoglobin; HDL-C: High-density lipoprotein cholesterol; Ht: Hematocrit; IGF-1: Insulin-like growth factor-1; LDH: Lactate dehydrogenase; LDL-C: Low-density lipoprotein cholesterol; LH: Luteinizing hormone; MMI: Methimazole; MRI: Magnetic resonance imaging; Pits: Platelets; PRL: Prolactin; RBC: Red blood cells; RTH: Resistance to thyroid hormone; SITSH: Syndrome of inappropriate secretion of TSH; T-Bil: Total bilirubin; TG: Triglyceride; Tg Ab: Anti-thyroglobulin antibody; TPO Ab: Anti-thyroid peroxidase antibody; TR: Thyroid hormone receptor; TRAb: Anti-TSH receptor antibody; TSH: Thyroid-stimulating hormone; UA: Uric acid; WBC: White blood cells.

**Acknowledgements**

We thank Dr. Yoshitaka Hayashi, Department of Genetics, Division of Stress Adaptation and Protection, Research Institute of Environmental Medicine, Nagoya University, for analysis of the germline mutations of TRβ.
Authors' contributions
HA drafted the manuscript. HA and RU performed clinical diagnosis, and treated the patient. RU supervised the writing of the report. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data and materials are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Endocrinology and Metabolism, Toyama Prefectural Central Rehabilitation Hospital and Support Center for Children with Disabilities, 36 Shimo-ino, Toyama-shi, Toyama 931-8517, Japan. 2 Department of Endocrinology, Diabetology and Metabolism, Toyama Prefectural Rehabilitation Hospital and Support Center for Children with Disabilities, 36 Shimo-ino, Toyama-shi, Toyama 931-8517, Japan.

Received: 7 August 2020 Accepted: 12 August 2021 Published online: 25 September 2021

References
1. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993;14(3):348–9.
2. Refetoff S, Dumitreascu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodinase. Best Pract Res Clin Endocrinol Metab. 2007;21(2):277–305.
3. Usala SJ, Bale AE, Gesundheit N, Weinberger C, Skeels MR, Singh H, Lentz GA, Nelson JC. Follow-up of newborns with elevated screening T4 concentrations. J Pediatr. 2003;143:296–301.
4. Parrilla R, Moxson AJ, McPherson JA, McClaskey JH, Weintraub BD. Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two “hot spot” regions of the ligand binding domain. J Clin Invest. 1991;88(6):2123–30.
5. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem. 1998;273(46):30175–82.
6. Sakurai A, Miyamoto T, Refetoff S, DeGroot LJ. Dominant negative transcriptional regulation by a mutant thyroid hormone receptor-beta in a family with generalized resistance to thyroid hormone. Mol Endocrinol. 1990(4)(12):1988–94.
7. Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stippled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab. 1967;27(2):279–94.
8. Weintraub BD, Gershengorn MC, Kourides IA, Fein H. Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med. 1981;95(3):339–51.
9. Lafranchi SH, Snyder DB, Sessers DE, Skeels MR, Singh H, Lentz G, Nelson JC. Follow-up of newborns with elevated screening T4 concentrations. J Pediatr. 2003;143:296–301.
10. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17(6):610–38.
11. Sivakumar T, Chaidaran S. Resistance to thyroid hormone in a patient with co-existing Graves’ disease. Thyroid. 2010;20(2):213–6.
12. Satoh H. Clinical features of primary hyperthyroidism caused by Graves’ disease admixed with resistance to thyroid hormone (H435T). Endocr J. 2010;57(8):687–92.
13. Ogawa K, Yoshida M, Hayashi Y, Murata Y, Miyata M, Oiso Y. A rare case of resistance to thyroid hormone coexisting with Graves’ disease. Endocrinol. 2011;140(2):318–9.
14. Fukata S, Brent GA, Sugawara M. Resistance to thyroid hormone in Hashimoto’s thyroiditis. N Engl J Med. 2005;352(5):517–8.
15. Aksoy DY, Gurlek A, Ringkananontu L, Weiss RE, Refetoff S. Resistance to thyroid hormone associated with autoimmune thyroid disease in a Turkish family. J Endocrinol Invest. 2005;28(4):379–83.
16. Satoh S, Sakai H. A family showing resistance to thyroid hormone associated with chronic thyroiditis and its clinical features: a case report. Endocr J. 2006;53(3):421–5.
17. Barkoff MS, Kocherginsky M, Anselmo J, Weiss RE, Refetoff S. Autoimmunity in patients with resistance to thyroid hormone. J Clin Endocrinol Metab. 2010;95(7):3189–93.
18. Kamoi K, Mitsuma T, Satoh H, Yokoyama M, Washiyama K, Tanaka R, Arii O, Takas N, Yamada T. Hyperthyroidism associated with a pituitary thyrotropin-secreting tumour with excessive secretion of thyrotropin-releasing hormone and subsequently followed by Graves’ disease in a middle-aged woman. Acta Endocrinol. 1985;110(3):373–82.
19. Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hiran O, Nakano S, Tei C. Thyrotropin-producing pituitary adenoma associated with Graves’ disease. Eur J Endocrinol. 2004;151(5):587–94.
20. Kamoun M, d’Herbomez M, Lemaire C, Fayard A, Desalouard R, Huglo D, Wemeau JL. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and Graves’ hyperthyroidism. Eur Thyroid J. 2014;3(1):60–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.